Trial Profile

SFX-01 After Subarachnoid Haemorrhage

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 09 Sep 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Sulforafan (Primary) ; Sulforafan (Primary)
Indications Subarachnoid haemorrhage
Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
Acronyms SAS
Sponsors Evgen Pharma; TheraCryf

Most Recent Events

19 Mar 2024 According to Evgen Pharma media release, Evgen Pharma plc has changed its name to TheraCryf
14 Jan 2020 Status changed from active, no longer recruiting to completed.
16 Jul 2019 Planned End Date changed from 1 Apr 2019 to 1 Sep 2019.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com